Commitments and Contingencies (Details) - USD ($)					1 Months Ended
	May 14, 2021	Apr. 14, 2021	Feb. 11, 2020	Sep. 12, 2018	Apr. 30, 2020	Jan. 31, 2019	Jun. 15, 2020	Jan. 31, 2020	Jun. 21, 2019
Other Commitments [Line Items]
Damages sought value	$ 67,125.83		$ 2,861,401.66	$ 761,401.66		$ 2,100,000
Unpaid wages							$ 300,000	$ 372,638	$ 30,428.71
severance								$ 300,000
Description of commitments					provide for an annual base salary of $400,000, provide for a performance bonus structure for a bonus of up to 50% of base salary upon the Company’s achievement of $2,000,000 EBITDA and additional performance bonus payments for the achievement of EBITDA in excess of $2,000,000 based on a percentage of the incremental increase in EBITDA (ranging from 10% of the incremental increase in EBITDA if the Company achieves over $2,000,000 and up to $7,000,000 in EBITDA, 8% of the incremental increase in EBITDA if the Company achieves over $7,000,000 and up to $12,000,000 in EBITDA and 3% of the incremental increase in EBITDA over $12,000,000), provide for a profits-based additional bonus of up to $250,000 in certain limited circumstances, and provide for one (1) year severance, plus a pro-rated amount of any unpaid bonus earned by him during the year as verified by the Company’s principal financial officer, if Mr. Galvin is terminated without cause. At the Company’s option, up to fifty (50%) percent of the EBITDA performance bonuses may be paid in restricted stock units if then available for grant under the Company’s Stock Incentive Plan. All other terms of the employment agreement remain in full force and effect.
Osang Healthcare Company, Ltd. [Member]
Other Commitments [Line Items]
Description of commitments		The Company has asserted that Osang materially breached a certain Managed Supply Agreement (“MSA”) entered into between the parties on October 12, 2020, pursuant to which the Company received on consignment <span style="color: #000000;">two million (2,000,000) units of Osang’s “Genefinder Plus RealAmp Covid-19 PCR Test” (the “Covid-19 Test”) for domestic and international distribution. The Company has also asserted that Osang breached the covenant of good faith and fair dealing, fraudulently induced it to enter into the MSA, and violated §349 of the New York General Business Law’s prohibition of deceptive business practices.</span>